Sarepta plays nice with the FDA, sets out plans for second accelerated Duchenne pitch by year's end
Attempting to mend a rather tense relationship with regulators, Sarepta has wrapped up talks with the FDA on how it should move forward with its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
